-

12:35:31 PM

TENX Stock News

TENX - Tenax Therapeutics Inc

02/03/23 8:19 AM

Nasdaq : TENX

offeringlow float

Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today the

RHEA-AI

neutral

02/01/23 4:31 PM

Nasdaq : TENX

low float

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

RHEA-AI

neutral

01/04/23 8:00 AM

Nasdaq : TENX

low float

Tenax Therapeutics Announces Reverse Stock Split

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that it

RHEA-AI

neutral

10/10/22 8:30 AM

Nasdaq : TENX

low float

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announces the

RHEA-AI

neutral

09/15/22 8:30 AM

Nasdaq : TENX

low float

Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that

RHEA-AI

neutral

05/25/22 8:30 AM

Nasdaq : TENX

low float

Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)

Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will host a key opinion leader webinar about TNX-201, in development as a potential treatment for pulmonary arterial...

RHEA-AI

neutral

05/23/22 8:30 AM

Nasdaq : TENX

low float

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the successful completion of its comparative pharmacokinetic study of TNX-201, for the treatment of pulmonary arterial...

RHEA-AI

positive

05/18/22 8:30 AM

Nasdaq : TENX

low float

Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and...

RHEA-AI

neutral

03/31/22 8:30 AM

Nasdaq : TENX

earningslow float

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the year ended December 31, 2021 and provided a business update. “With the advancement of our proprietary...

RHEA-AI

neutral

03/30/22 5:00 PM

Nasdaq : TENX

conferenceslow float

Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that two presentations will be made at the upcoming American College of Cardiology Scientific Sessions featuring the Company’ s...

RHEA-AI

neutral

TENX Data

IndustryResearch and Development in Biotechnology
Websitewww.tenaxthera.com
CeoAnthony DiTonno
Security nameTenax Therapeutics Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code8731
Employees8
Tags
- Health Technology
- Medical Specialties
Address1 Copley Pkwy Ste 490
StateNorth Carolina
CityMorrisville
Zip27560-9693
CountryUS
Phone19198064414

About Tenax Therapeutics Inc

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). Tenax plans to advance a delayed release oral formulation of imatinib, designed to avoid the gastric irritation, into a single pivotal trial pursuant to the 505(b)(2) pathway.